These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36149807)

  • 21. Study of Efficacy of Injection Remdesivir in Patients of COVID-19.
    Chaudhary BR; Dudhrejia PJ; Gambhir RM; Rathod MM
    J Assoc Physicians India; 2023 Apr; 71(4):11-12. PubMed ID: 37355792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Remdesivir in 20 Children with COVID-19-Case Series-.
    Manabe S; Mizuno S; Jinda T; Kasai M
    Biol Pharm Bull; 2022 Dec; 45(12):1853-1856. PubMed ID: 36216548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
    Gallo JM
    Clin Transl Sci; 2021 May; 14(3):1082-1091. PubMed ID: 33404204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic.
    Pashaei Y
    Drug Discov Ther; 2021 Jan; 14(6):273-281. PubMed ID: 33390567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
    Coelho L; Falcão F; Póvoa P; Viegas E; Martins AP; Carmo E; Fonseca C; Campos L; Mansinho K; Carmo I; Soares J; Solano M; Mendes D; Miranda AC; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Sci Rep; 2023 Mar; 13(1):4482. PubMed ID: 36934143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection.
    Vermillion MS; Murakami E; Ma B; Pitts J; Tomkinson A; Rautiola D; Babusis D; Irshad H; Seigel D; Kim C; Zhao X; Niu C; Yang J; Gigliotti A; Kadrichu N; Bilello JP; Ellis S; Bannister R; Subramanian R; Smith B; Mackman RL; Lee WA; Kuehl PJ; Hartke J; Cihlar T; Porter DP
    Sci Transl Med; 2022 Feb; 14(633):eabl8282. PubMed ID: 34968150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.
    Santos Bravo M; Alonso R; Soria D; Sánchez Palomino S; Sanzo Machuca Á; Rodríguez C; Alcamí J; Díez-Fuertes F; Simarro Redon À; Hurtado JC; Fernández Avilés F; Bodro M; Rubio E; Villanueva JL; Vergara A; Castro P; Tuset M; Cuesta G; Puerta P; García C; Mosquera Gutiérrez MDM; Martínez MJ; Vila J; Soriano A; Marcos MÁ
    Microbiol Spectr; 2022 Dec; 10(6):e0244822. PubMed ID: 36354320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19.
    Chakraborty A; Diwan A; Chiniga V; Arora V; Holkar P; Thakur Y; Tatake J; Barton R; Holkar N; Pandey R; Pond B
    PLoS One; 2022; 17(12):e0278963. PubMed ID: 36584166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events.
    Dang A; Vallish BN; Dang S
    Indian J Med Ethics; 2020; V(3):202-207. PubMed ID: 33295289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Remdesivir in Patients with COVID-19.
    Afshar ZM; Hosseinzadeh D; Hosseinzadeh R; Babazadeh A; Allahgholipour A; Sio TT; Sullman MJM; Carson-Chahhoud K; Barary M; Ebrahimpour S
    Infect Disord Drug Targets; 2023; 23(7):1-13. PubMed ID: 37165585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 35. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breastfeeding and Respiratory Antivirals: Coronavirus and Influenza.
    Anderson PO
    Breastfeed Med; 2020 Mar; 15(3):128. PubMed ID: 32129667
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
    Montastruc F; Thuriot S; Durrieu G
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
    Nasir M; Talha KA; Islam T; Saha SK; Selina F; Parveen RA
    Mymensingh Med J; 2020 Apr; 29(2):481-487. PubMed ID: 32506110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.
    Ahmed A; Munoz FM; Muller WJ; Agwu A; Kimberlin DW; Galli L; Deville JG; Sue PK; Mendez-Echevarria A; Humeniuk R; Guo S; Rodriguez L; Han D; Hedskog C; Maxwell H; Palaparthy R; Kersey K; Rojo P;
    Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38332740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.